The rescheduling headlines were full of industry celebration. But dig into the details and you’ll find that the wins are real — just a lot narrower than general coverage suggested. And not remotely close to evenly distributed across the board.
By now you’ve probably seen the press releases, the LinkedIn posts, the stock jumps. The federal rescheduling of medical cannabis to Schedule III is being celebrated as some monumental moment for the cannabis industry — and in some ways, it genuinely is. I don’t want to minimize it, I swear. But in the weeks since the DOJ’s April 23rd announcement, a more complicated picture has emerged for cannabis operators trying to figure out what any of this actually means for their business.
If you missed our earlier pieces in this series — what the rescheduling order actually does and what it means for patients — those are good starting points. But this one is for operators, owners, and industry professionals. Specifically, it’s for those trying to figure out who wins, who doesn’t, and what the smart move is right now.
Spoiler Alert! The answer depends almost entirely on your license type, your state, and how much risk you’re willing to take on.
In short? Just another day in our historically complex industry.
The 280E Win Isn’t Universal — Here’s Who Gets It
Let’s start with the biggest headline: 280E tax relief. Section 280E of the Internal Revenue Code has been the financial albatross around the industry’s neck since the 1980s. It prohibits standard business deductions for companies trafficking in Schedule I or II substances — meaning cannabis operators have been unable to deduct ordinary expenses like rent, payroll, utilities, and marketing.
The result has been effective tax rates that can hit 70% or higher. Obviously, this makes it genuinely difficult to run a profitable cannabis business even with a thriving state market.
With medical cannabis now classified as Schedule III, state-licensed medical operators are no longer subject to 280E’s deduction disallowance. That’s a real, meaningful, and immediate financial win. The ability to run your business on a level tax playing field with virtually every other industry in the country shouldn’t be a luxury but for cannabis brands it is.
Here’s the critical caveat that’s getting glossed over: this relief applies to medical cannabis operations only.
If your business touches recreational sales — even in a state where adult-use is fully legal — those sales remain entirely subject to 280E. For multistate operators and dual-license businesses, the accounting implications are significant. It also makes the relief substantially less dramatic than the headlines implied.
The 280E win is real. It’s also scoped, conditional, and — as we’ll cover below — still legally uncertain. Don’t restructure your business before talking to a cannabis-specialized CPA and attorney!
The DEA Registration Gamble: Opportunity or Liability?
Within days of the DOJ announcement, the DEA launched its Medical Marijuana Dispensary Registration Portal — a voluntary opt-in system through which state-licensed medical operators can apply for formal federal recognition under the new Schedule III framework.
There’s a full breakdown from Marijuana Moment here.
The first thing to understand: registration is optional, not mandatory. Your 280E relief as a state-licensed medical operator does not depend on DEA registration. The rescheduling order itself makes clear that Schedule III placement is based on state license status — full stop. DEA registration is a separate layer that some businesses will pursue for strategic reasons, but it’s not a requirement for the tax benefits.
So what do you actually get by registering?
In theory: formal federal recognition, enhanced legitimacy with banking partners, and a cleaner paper trail for any future federal compliance requirements. In practice: that’s still being worked out, and the costs and risks of applying are not trivial.
Here’s what the application currently requires:
- A $794 annual fee, currently payable only through PayPal (additional payment methods reportedly coming)
- Detailed security information for your facility
- Complete supplier lists
- State license documentation
- Criminal history disclosures
- Names, dates of birth, and Social Security numbers for all employees with access to controlled substances
That last point deserves extra attention. If you’re planning to apply, give your staff advance notice and a genuine option to opt out before their personal information goes into a federal DEA database. That’s not a small ask, and employees have a right to understand what they’re being enrolled in.
High-profile operators like Trulieve have moved quickly to pursue federal registration — a signal that the largest MSOs see strategic value in being among the first federally compliant medical cannabis operators in the country. Whether that early-mover advantage holds up depends heavily on what happens in court over the next several months.
Dual-License Operators: Left in the Cold
If you operate in a dual-license state — meaning your business serves both medical and recreational customers — the rescheduling picture gets significantly more complicated. And in some ways, significantly less exciting.
The DEA registration application directly asks whether your business handles recreational marijuana.
Cannabis attorneys at Harris Sliwoski have been clear: an honest “yes” will very likely result in a denial. Which puts dual-license operators in an uncomfortable position — apply honestly and get rejected, or don’t apply and forgo whatever strategic benefits registration might eventually offer.
And even setting registration aside, the 280E picture for dual-license operators is messy. Really messy if you don’t have good accounting in place.
Your medical sales get the relief. Your recreational sales don’t. That means rigorous revenue separation in your accounting is now more important than ever.
This isn’t just for tax purposes. It’s mostly because you want airtight documentation if the IRS ever scrutinizes how you’ve classified your operations. If you’re a dual-license operator and your books aren’t already set up to clearly separate medical and recreational revenue streams, that’s the first call you should be making.
Dual-license operators aren’t being penalized by rescheduling — they’re just not being rescued by it the way medical-only operators are. The rec side of your business is exactly where it was on April 22nd.
Medical-Only States: The Quiet Winners
While the loudest celebrations have come from the largest multistate operators, the businesses that stand to benefit most cleanly and immediately from Schedule III are operators in medical-only states. And honestly, they’re not getting nearly enough attention in this conversation.
In a medical-only state, like Florida for example, there’s no recreational revenue to complicate the picture. That means the entire operation is already scoped to state-licensed medical sales. That also means full 280E relief across your business. Plus, a clean DEA registration application without the dual-license disclosure problem. And a straightforward path to the new federal framework.
There’s another downstream benefit worth watching: medical program enrollment.
As Hemp Gazette has covered, the 280E relief is expected to at least partially pass through to consumers as lower prices on medical products — widening the price gap between medical and recreational purchases. This could give consumers in dual-license states more financial incentive to obtain or renew a medical card.
For medical-only operators, this is less relevant. But for dispensaries in states where adult sales account for more than their med sales, or ones that are watching legalization on the horizon, it’s worth noting that a robust medical program now has clearer economic advantages for patients than it did before.
If you’re a medical-only operator and you haven’t already had a conversation with your accountant about how to properly position your business to take advantage of 280E relief, that conversation needs to happen ASAP.
The Litigation Wildcard Nobody’s Talking About
Most industry coverage is either burying or skipping this point entirely: none of these wins are guaranteed to hold up.
Cannabis attorneys at Harris Sliwoski have assessed the likelihood that this rescheduling order faces a successful legal challenge at greater than 50%. The mechanism used to reschedule — 21 USC 811(d)(1), the international treaty provision — is legally novel and largely untested in this context. Opponents of rescheduling, led by the advocacy group Smart Approaches to Marijuana (SAM), filed a suit challenging whether the DEA and DOJ exceeded their authority.
If a court issues a stay pending litigation — which is a real possibility — some or all of the protections and benefits that went into effect on April 23rd could be paused while the legal challenge plays out. That includes the 280E relief. It includes the DEA registration framework. And it includes the legitimacy that early-registration operators like Trulieve are betting on.
There’s also the congressional angle. A House appropriations subcommittee voted on April 30 to advance spending bill language that would block federal funds from being used to further the rescheduling process. While similar riders have failed to become law in previous years, the political environment is more volatile than it’s been in a while. We’ll cover that fight in full in Part 4 of this series.
The smart move right now is to understand the benefits, position your business to take advantage of them — and do it in a way that doesn’t leave you overexposed if the legal or political landscape shifts.
The Bottom Line for Operators
The Schedule III rescheduling of medical cannabis is a genuine milestone for the industry. The 280E relief is real. The pathway to banking normalization and insurance engagement is real. The signal to the broader business world that cannabis is a legitimate industry is real.
But the wins are not distributed evenly, the risks are not trivial, and the legal durability of everything that happened on April 23rd is still an open question. Medical-only operators are in the best position to benefit cleanly and immediately. Dual-license operators need nuanced accounting strategies and careful legal counsel. Everyone — regardless of license type — should be watching the June 29 hearing and the SAM litigation closely.
This is a moment to move thoughtfully, not reactively. The businesses that will benefit most from rescheduling over the long term are the ones that take the time to understand exactly what changed — and exactly what didn’t.
Up next in this series: Congress is actively working to kill rescheduling before the June 29 hearing even happens. We’ll break down who’s behind it, how the appropriations rider strategy works, and what it means if they actually succeed — coming soon to ATC.
